Butterfield JH, Weiler CR.Treatment of hypereosinophilic syndromes-the first 100 years[J]. Semin Hematol, 2012, 49(2):182-191.
[2]
Montgomery ND, Dunphy CH, Mooberry M, et al. Diagnostic complexities of eosinophilia[J]. Arch Pathol Lab Med, 2013, 137(2): 259-269.
[3]
Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia[J]. J Allergy Clin Immunol, 2010, 126(1): 39-44.
[4]
Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome[J]. J Allergy Clin Immunol, 2010, 126(1): 45-49.
[5]
Hyogo M, Kamitani T, Oguni A, et al. Acute Necrotizing eosinophilic myocarditis with giant cell infiltration after remission of idiopathic thrombocytopenic purpura[J]. Intern Med, 1997, 36(12): 894-897.
[6]
Tong LS, Wan JP, Cai X, et al. Global Hypoperfusion: A New Explanation of Border Zone Strokes in Hypereosinophilia[J]. CNS Neurosci Ther, 2014, 20(8): 794-796.
[7]
Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2014, 89(3): 325-337.
[8]
Khwaja GA, Duggal A, Kulkarmi A, et al. Hypereosinophilia-an unusual cause of multiple embolic strokes and multi-organ dysfunction[J]. J Clin Diagn Res, 2013, 7(10):2316-2318.
[9]
王兆辉,姚慧.白细胞介素-17对哮喘小鼠嗜酸性粒细胞的影响[J].山东大学学报(医学版),2011,49(5):58-60. WANG Zhaohui, YAO Hui. Effects of interleukin-17 on eosinophils in mice with asthma[J]. Journal of Shandong University(Health Sciences), 2011, 49(5):58-60.
[10]
Rofosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes[J]. J Allergy Clin Immunol, 2013, 131(2): 461-467.
